

Edward J Filippone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3909432/publications.pdf>

Version: 2024-02-01

33
papers

990
citations

759055

12
h-index

434063

31
g-index

33
all docs

33
docs citations

33
times ranked

917
citing authors

#	ARTICLE	IF	CITATIONS
1	Associated Focal and Segmental Glomerulosclerosis in the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1984, 310, 669-673.	13.9	587
2	Humoral Immune Response and Allograft Function in Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2015, 66, 337-347.	2.1	46
3	Chronic Kidney Disease Linearly Predicts Outcomes After Elective Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2016, 31, 175-179.e2.	1.5	37
4	Transplant glomerulopathy. <i>Modern Pathology</i> , 2018, 31, 235-252.	2.9	30
5	Segmental Arterial Mediolysis: Report of 2 Cases and Review of the Literature. <i>American Journal of Kidney Diseases</i> , 2011, 58, 981-987.	2.1	29
6	Sensitization trends after renal allograft failure: the role of <sc>DQ</sc> eplet mismatches in becoming highly sensitized. <i>Clinical Transplantation</i> , 2016, 30, 71-80.	0.8	28
7	Hemophagocytic lymphohistiocytosis: an update for nephrologists. <i>International Urology and Nephrology</i> , 2016, 48, 1291-1304.	0.6	20
8	The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	0.9	19
9	Humoral immunity in renal transplantation: epitopes, <sc>C</sc>w and <sc>DP</sc>, and complement-activating capability – an update. <i>Clinical Transplantation</i> , 2015, 29, 279-287.	0.8	18
10	The specificity of acute and chronic microvascular alterations in renal allografts. <i>Clinical Transplantation</i> , 2013, 27, 790-798.	0.8	14
11	Goal-directed antihypertensive therapy: Lower may not always be better. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 123-133.	0.6	14
12	Adrenocorticotrophic hormone analog use for podocytopathies. <i>International Medical Case Reports Journal</i> , 2016, Volume 9, 125-133.	0.3	13
13	Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform. <i>Immunologic Research</i> , 2018, 66, 584-604.	1.3	13
14	Acute Kidney Injury Following Failed Total Hip and Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2018, 33, 3297-3303.	1.5	12
15	Enhancing Natural Killer and CD8⁺ T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8⁺ T Cells with HLA-E Monospecific Monoclonal Antibodies. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2019, 38, 38-59.	0.8	12
16	Tacrolimus-induced thrombotic microangiopathy: natural history of a severe, acute vasculopathy. <i>Clinical Nephrology</i> , 2012, 77, 79-84.	0.4	12
17	Membranous nephropathy in the kidney allograft. <i>Clinical Transplantation</i> , 2016, 30, 1394-1402.	0.8	10
18	Normoglycemic Diabetic Nephropathy: The Role of Insulin Resistance. <i>Case Reports in Nephrology and Urology</i> , 2014, 4, 137-143.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Association Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure–Lowering Therapy. <i>JAMA Network Open</i> , 2021, 4, e2128980.	2.8	9
20	Antibodies to cryptic epitopes on HLA class I and class II heavy chains bound to single antigen beads: Clinically relevant?. <i>Transplant Immunology</i> , 2021, 69, 101482.	0.6	9
21	Acute kidney injury after hip or knee replacement: Can we lower the risk?. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 263-276.	0.6	8
22	The J-Curve Revisited. <i>Cardiology in Review</i> , 2012, 20, 253-258.	0.6	6
23	Immunosuppressive treatment of idiopathic membranous nephropathy: the dilemma continues. <i>Clinical Nephrology</i> , 2013, 79, 143-153.	0.4	6
24	De Novo Fibrillary Glomerulonephritis (FGN) in a Renal Transplant with Chronic Hepatitis C. <i>Case Reports in Transplantation</i> , 2013, 2013, 1-5.	0.1	5
25	Optimizing the assessment of pathogenic anti-HLA antibodies. <i>American Journal of Transplantation</i> , 2021, 21, 431-432.	2.6	4
26	Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines. <i>Vaccines</i> , 2022, 10, 339.	2.1	4
27	Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients. <i>Antibodies</i> , 2022, 11, 18.	1.2	4
28	Noninvasive Assessment of the Alloimmune Response in Kidney Transplantation. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 548-560.	0.6	3
29	Secondary Membranous Nephropathy Associated with Guillain-Barré Syndrome. <i>Case Reports in Nephrology and Urology</i> , 2013, 3, 34-39.	1.5	2
30	Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg. <i>Vaccines</i> , 2021, 9, 680.	2.1	2
31	Controversies in Hypertension II: The Optimal Target Blood Pressure. <i>American Journal of Medicine</i> , 2022, 135, 1168-1177.e3.	0.6	2
32	Controversies in Hypertension I: The Optimal Assessment of Blood Pressure Load and Implications for Treatment. <i>American Journal of Medicine</i> , 2022, 135, 1043-1050.	0.6	2
33	The diastolic blood pressure J-curve revisited: An update. <i>American Heart Journal Plus</i> , 2021, 12, 100065.	0.3	1